This single-center, prospective study will assess safety and effectiveness of 360 degree viscodilation followed by up to 360 degree trabeculotomy used in patients with early or moderate open-angle glaucoma in a real-world setting either as a standalone procedure in pseudophakic patients (or phakic) or combined with phacoemulsification cataract procedures.

Medication usage, IOP and secondary surgical procedures necessary for IOP control will be analyzed during the follow-up period.

Inclusion Criteria:

• diagnosed with open-angle glaucoma including pigmentary and pseudoexfoliative glaucoma
• 0-3 topical ocular hypotensive medications at preoperative baseline. Fixed combinations counted as number of components
• Open angles (Shaffer grade ≥3)
• early or moderate glaucoma (based on visual field)
• Subjects with a combined procedure should have had uncomplicated cataract surgery (i.e. intact and centered capsulorrhexis, intact posterior capsular bag, no evidence of zonular dehiscence or rupture, well centered IOL)

Exclusion Criteria:

• Any of the following prior treatments for glaucoma:

  • Suprachoroidal stent
  • Laser trabeculoplasty ≤6 months prior to OMNI procedure
  • Trabecular bypass implanted ≤6 months prior to OMNI procedure
  • Trabeculectomy or other bleb forming procedure including Xen, Express, glaucoma draining device/valve
  • Prior canaloplasty, goniotomy, or trabeculotomy

• Forms of glaucoma other than OAG including: acute angle closure, traumatic, congenital, malignant, uveitic or neovascular glaucoma

• Under treatment with oral carbonic anhydrase inhibitor at the preoperative visit

• Clinically significant ocular pathology, other than age-related cataract and glaucoma. (e.g. wet AMD, uveitis, corneal edema, proliferative diabetic retinopathy, optic neuritis in medical history)